Corcept Therapeutics announced its preliminary financial results for Q4 and 2023, and approved a program to repurchase up to $200 million of its common stock.
AI Assistant
CORCEPT THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.